BioSpace News Archive

Rising funds by private and public organizations to support ongoing research and development activities, high demand for protein and nucleic acid sequencing, and technological advancements in bioinformatics sector are key factors fueling global market growth.

MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2021.

High prevalence of cancer, technical knowledge about gene expression and favorable research funding scenario would drive market growth.

Increasing investments in research and development activities, growing demand for bioinformatics in various application sector, and rising demand for data integration of huge data are key factors fueling global market growth.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that is has commenced an underwritten public offering of 14,000,000 shares of its common stock. In connection with this offering

Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the “Company” or “Panbela”), today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company at a price to the public of $3.00 per share, less underwriting discounts and commissions.

N2 Biomedical, a leading provider of coating and surface treatment solutions to the medical device industry, is pleased to announce that Keith Edwards has been appointed Chief Executive Officer.

Kiromic BioPharma, Inc. announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $40 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced today the upsize and pricing of its initial public offering of 7,000,000 shares of its common stock at a public offering price of $18.00 per share

Advancements in healthcare sector, and growing awareness related to assisted reproductive technology.